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Abstract: The synthesis, characterization and antiproliferative activity 
of the bis-metallic Ru-Zn complex [RuCp(PPh3)2-µ-dmoPTA-
1кP:2k2N,N’-ZnCl2](CF3SO3) (4) and the monometallic Ru complex 
[RuCp(PPh3)2(dmoPTA-1kP)](CF3SO3) (5) are presented. Against 
human lung, cervix, breast, and colon solid tumour cell lines, the 
complex 4 showed an enhanced antiproliferative activity (GI50 = 30-83 
nM) when compared to its parent complex [RuCp(PPh3)2(HdmoPTA-
1kP)](CF3SO3) (2). Additionally, it was significantly more active 
against the breast cancer cell line T-47D than its sibling cobalt 
complex [RuCp(PPh3)2-µ-dmoPTA-1kP:2k2N,N’-CoCl2](CF3SO3) (3). 
When evaluated against non-tumour human cell line BJ-hTert the 
complex 4 showed to be 3-8 times less active, indicating a large 
selectivity against tumour cell, while compound 5 resulted not 
selective. 
Introduction 
Ruthenium(II)-based complexes have emerged as promising 
antitumor and antimetastatic agents with potential uses in 
platinum(II)-resistant tumours. In fact, some of them have shown 
broad diversity, in terms of activity, toxicity, and mechanisms of 
action due to a combination of chemical and biological 
properties.[1] Nevertheless, the platinum(II) complexes with 
antiproliferative properties show a similar ligand exchange kinetic 
than ruthenium(II)-anticancer drugs, which is crucial for displaying 
a significant anticancer activity.[2]  
Stabilized Ru(II) complexes containing adequate ligands 
display the suitable redox and ligand-exchange properties 
needed to react with cancer cells. An accurate choice of the 
ligands coordinate to the metal could provide a selective 
antiproliferative activity of the formed complexes, killing the 
cancer cells selectively.[3,4] Additionally, the ligands are also 
useful for providing the optimal solubility for the complex both in 
water, the main component of living organism, and organic 
systems, such as the membrane cells. The 
hydrophilic/hydrophobic balance of a specie determines the in 
vivo behaviour and efficient under physiological conditions.[3b,4] 
The first report on the use of a water-soluble phosphine as ligand 
in developing anticancer ruthenium complexes dates back to 
2011, when Dyson et al., prepared a family of organometallic 
ruthenium compounds  containing the hydrophilic phosphine 
1,3,5-triaza-7-phosphaadamantane (PTA), which displayed 
significant anticancer activity towards different cancer cell lines, 
and particularly against platinum resistant cancer cells.[4b-d] 
Hydrolysis and the loss of one or more ligands are important 
processes in the mechanism of action of these water soluble 
ruthenium drugs due to increasing the number of potential 
targetable molecules.[1d,3-5] We have been interested in this field 
for years, firstly synthetizing and studying the family of water-
soluble ruthenium complexes [RuCpX(L1)(L2)]n+ (X = Cl; L1 ,L2 = 
PPh3,PTA, mPTA, mTPPMS).[6] Later on we studied also the 
effect on the antiproliferative activity of the bis-N-methylated PTA 
N,N’-dimethyl-1,3,5-triaza-7-phosphaadamantane (dmPTA) and 
its derivative 3,7-H-3,7-dimethyl-1,3,7-triaza-5-
phosphabicyclo[3.3.1]nonane (HdmoPTA).[7,8,9,10] This last ligand 
can be easily deprotonated and the resulting neutral  3,7-
dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane) (dmoPTA) 
is able to coordinate metals through the soft P and the two hard 
NCH3 atoms, behaving in the latter case as a chelate.[11] The 
antiproliferative activity of the complex 
[RuCpCl(PPh3)(HdmoPTA-1κP)](CF3SO3) (1) (the so-called 1st 
generation) against colon cancer cells was significant better (GI50 
= 1.7 µM) than that showed by cisplatin, that is  currently used in 
anticancer therapy.[8] The substitution of the chloride in 1 by one 
PPh3 led to complex [RuCp(PPh3)2(HdmoPTA-
1κP)](CF3SO3)2·(2) (the so-called first member of the 2nd 
generation), which is more soluble in organic solvent, showing a 
substantial enhancement of the antiproliferative activity with 
respect to the starting complex 1.[12] Elimination of the  HdmoPTA-
proton in 1 and further reaction with CoCl2 provided the Ru-Co 
complex [RuCp(PPh3)2-µ-dmoPTA-1kP:2k2N,N’-CoCl2](CF3SO3) 
(3) (the second member of the 2nd generation), which showed a 
significant better antiproliferative activity than 1 (Figure 1), despite 
Co(II) is not particularly known for its antimetastatic properties.[13] 
The fact that the CoCl2 is not an antiproliferative agent and that 
the antimetastatic activity of the Ru-Co complex is clearly and 
significantly better than the monometallic Ru starting complex led 
us to propose that complex 3 acts as a “Troyan Horse” that 
introduce both metals into the cell. To obtain a new example of 
this family of bimetallic complexes with possibly better 
antiproliferative activity but also amenable to be studied in 
dissolution by NMR, a diamagnetic metal should be coordinated 
to the dmoPTA-NCH3 atoms.    
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The hetero-metal selected was the diamagnetic Zn(II) that is an 
important component of some biological systems (i.e. as cytosolic 
Cu/Zn superoxide dismutase (SOD)).14 
Results and Discussion 
The Ru-Zn complex was initially synthetized by a procedure 
similar to that used for 3,[13] by reaction of 2 with one equivalent 
of potassium tert-butoxide (t-BuOK) and further with one 
equivalent of ZnCl2 in EtOH (Scheme 1, path i). This synthetic 
procedure is very sensitive to reaction conditions and a new one 
more robust is needed to obtain enough product to be studied. 
Pure deprotonated complex [RuCp(PPh3)2(dmoPTA-
1kP)](CF3SO3) (5) was synthetized by reaction of 2 with 1.1 
equivalent of t-BuOK in THF (Scheme 1, path ii). The complex 5 
is practically insoluble in water (S25ºC,H2O = 0.5 mg/mL) while it is 
significant soluble in a variety of organic solvents such as CHCl3, 
THF, etc. This complex is stable in solution and solid state under 
N2 for months but under air some evidences of decomposition 
(31P{1H} NMR) are observed after one month in solid state and 
two days dissolved in CHCl3. Reaction of 5 with ZnCl2 in EtOH is 
a robust method to obtain the Ru-Zn complex (Scheme 1, path iii). 
The product was characterized by elemental analysis, IR and 
NMR spectroscopy as the expected bis-metallic Ru-Zn complex 
[RuCp(PPh3)2-µ-dmoPTA-1kP:2k2N,N’-ZnCl2](CF3SO3) (4). 
The 1H NMR of 4 was assigned by using 1H-1H COSY, 1H-13C 
HMBC and 1H-13C HSQC (see Figures S1-S6). The signals and 
chemical shift are those expected for the proposed complex 
composition in which the most interesting feature is the presence 
of two broad singlets, very close in chemical shift (2.15; 2.16 ppm), 
that could only be assigned to the NCH3 groups. This shows that 
the methyl groups are chemically different. In contrast, the 13C{1H} 
NMR shows only a broad signal ascribable to both NCH3. Finally, 
the 31P{1H} NMR only showed the existence of one unique specie 
with phosphorus in dissolution with the expected signal pattern for 
the complex: a doublet for the PPh3 ligand at 37.39 ppm and a 
triplet at -15.10 ppm due to the dmoPTA (2JPP = 39.2 Hz). Both 
signals arise at similar chemical shift than those for starting 
complex 2 (38.44; -13.94 ppm) with similar coupling constant 
(39.4 Hz).[12] The single crystal X-ray diffraction structure of 4 
showed that the asymmetric unit contains two OTf anions  and 
two enantiomeric cationic Ru-Zn complexes (Figure 2, Table S1). 
The complex units are formed by the combination of the 
deprotonated moiety {RuCp(PPh3)2(dmoPTA-1кP)}+, which is 
similar to that in the starting complex, and one {ZnCl2} moiety 
chelated to the NCH3 atoms. The coordination sphere of the 
ruthenium atom displays a piano-stool geometry constituted by a 
η5-Cp, two PPh3 and a dmoPTA unit by its P atom (Figure 2). The 
Cp-ring is essentially planar with the larger separation from the 
overall-plan-Cp of only 0.0047 Å (C38) somewhat shorter than 
that in 2·(0.0089 Å, C84) and 3·(0.0079 Å, C39).[12,13] The Ru-
Cpcentroid distance (1.894 Å) is almost equivalent to that found for 
2 and 3 (1.886 to 1.893 Å), and is similar to those found in other 
{RuCp}-complexes (from 1.836 to 1.929 Å; mean 1.893 Å).[15] The 
angle between the Cp-centroid plane and the P1–Ru1–P2 plane 
was found to be 46.6(1)°, which is virtually identical to that 
observed in 3 (46.9(9)o) but ca. 1.3o smaller than those found for 
2.[12,13] These values are considerably shorter than that found for 
complexes [RuClCp(PPh3)-μ-dmoPTA-1kP:2k2N,N′-MQ] (M = Co, 
Ni, Zn, Q = acac, Cl2), which are in the range  53.7(2) - 56.85(0)° 
(average: 55.2°).[11b,c] The dihedral angles between the dmoPTA 
atoms vary from 52.4(5)-51.6(3) to 51.8(4)-52.7(4)o in agreement 
with those observed in related complexes [RuClCp(PPh3)-μ-
dmoPTA-1kP:2k2N,N′-MCl2] (M = Co, Ni, Zn) moiety (52.2(1)-
54.9(2)o (average: 53.6o).[11a] The Cl1-Zn1-Cl2 angle is 121.3(8)º, 
which is close to that found in parent complex [RuClCp(PPh3)- μ-
dmoPTA-1kP:2k2N,N′-ZnCl2] (121.8(4)º).[11a] The triflate is located 
(Figure 2) between the C45 and F1T atoms (C45-H45B···F1T = 
3.192(6) Å, H45B···F1T = 2.488(4) Å).[12,13,15]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. GI50 values (nM) for the 2nd generation ruthenium organometallic 
complexes against human solid tumor cells lines A549, HBL-100, HeLa, 
SW1573, T-47D and WiDr.  
Scheme 1. Synthesis of 4·and 5; path i): t-BuOK / EtOH / ZnCl2, r.t.; ii): t-BuOK 
/ THF, r.t. and iii): EtOH / ZnCl2, r.t 
Figure 2. Perspective view and atom numbering selection of 4, showing the 
two six-membered rings around the metal with a pseudo-chair conformation 
which form enantiomeric pairs. Dashed line represent the selected 
intermolecular interaction. 
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The structural core of 4 displays a remarkable similarity to that 
of 3,[13] especially if one takes into consideration their CH3 groups 
(Figure 3). In fact, the disposition of the dmoPTA ligand lays the 
methyl groups in different chemical environment: one of them is 
located in front of the Cp and the other one is near to the aromatic 
rings. The crystal packing diagram (Figure 4) shows weak 
intermolecular interactions among the molecules (C36-H36···Cl2 
= 3.586(7), H36···Cl2 = 2.804(2) Å) and C–H/π interactions 
among adjacent phenyl–C–H groups and aromatic centroids 
(centroid-to-C–H distances from 3.366(5) to 3.566(6) Å), which 
were found larger than those found for 2·and 3 (range from 
3.183(5) to 3.470(5) Å).[12,13]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The complex 5 was characterized by elemental analysis, IR 
spectroscopy and NMR, supporting that the complex is 
constituted by a Ru atom coordinated with a piano-stool geometry 
to a η5-Cp, two PPh3 and one deprotonated dmoPTA by the P 
atom. The 31P{1H} NMR shows a doublet at 43.07 ppm (2JPP = 
38.24 Hz) due to the PPh3 and a triplet at -7.42 ppm 
corresponding to the dmoPTA, which are significantly shifted to 
down field respecting the protonated parent complex 2 (38.44 
ppm PPh3; -13.94 ppm dmoPTA) but the coupling constant is 
similar (39.4 Hz). The 1H NMR also shows the clear effect 
produced by the deprotonation, being the NCH3 protons more 
shielded than in the protonated complex (a broad singlet at 2.04 
ppm for 5; two broad singlets at 2.35 and 2.36 ppm for 2) but also 
the Cp, which is far from the deprotonation site, is shifted to upper 
field (4.78 ppm for 5; 4.90 for 2). In contrast, the 13C{1H} NMR is 
similar for both complexes (for example: 43.90 ppm, 44.01 ppm 
(5 NCH3); 43.35 ppm, 43.41 ppm (2 NCH3); 85.15 ppm (5 Cp); 
85.51 ppm (2 Cp). 
The antiproliferative activity of 4 and 5 was studied by the 
standard protocol (see SI) on six human solid tumour cells lines 
together with those for 2 and 3[12,13] and cisplatin; which were also 
tested for the sake of comparison (Table 1). In order to look for 
selectivity, we tested also compounds 4 and 5 against the non-
tumour human cell line BJ-hTert. 
Complex 5 showed a similar antiproliferative activity than the 
starting complex 2 and therefore the protonation/deprotonation of 
the of the complex unit {[RuCpCl(PPh3)(dmoPTA-1kP)}+ does not 
have a significant influence on its biological activity. In clear 
contrast and as expected, the new Ru-Zn (4) displays a better 
activity (1.2-2.5 times) than the sibling Ru-Co (3) and much better 
(26-426 times) than cisplatin. It is important to point out that 
complex 4 showed to be 3-8 times more active against the tumour 
cell lines than against the tested non-tumour cell line, indicating 
its large selectivity versus tumour cells. In contrast, complex 5 
resulted no selective. 
Complex 4·was found to be very stable, more than the Ru-Co 
complex 3, in the time needed for the antiproliferative experiments 
(i.e. 48 h) in a mixture of DMSO-d6/cell-culture-medium. A very 
small (less than 3 %) release of PPh3 was observed after one day 
which remained unvaried during one additional day. Similar 
experiments made in CDCl3 and DMSO-d6 showed that complex 
4 is significantly more stable than complex 3 in these solvents. 
The dissolution of 4 in DMSO-d6 led to the partial release of 
{ZnCl2}, giving rise to the complex 5. The reaction was not 
completed after 25 h and some small amount (< 5%) of released 
PPh3 and complexes {[RuCpCl(PPh3)(dmoPTA-1kP)}+,[10] and 
[RuCpCl(PPh3)-µ-dmoPTA-1kP:2k2N,N’-ZnCl2][11a] were 
observed. After 74 h under air at 40 oC, the largest signals 
observed by 31P{1H} NMR were still those of 4 (see SI). 
Complex 4 in CDCl3 slowly releases a PPh3 to give the complex 
[RuCpCl(PPh3)-µ-dmoPTA-1kP:2k2N,N’-ZnCl2][11a] and the 
starting complex 2 (see SI), products that are obtained also with 
Table 1. GI50 values (µM) of 2, 3, 4 and 5 and cisplatin against a representative human solid tumor and, 4 and 5 versus a non-tumour cell line.b 
 
 Cell line (origin) 
Entry A549 
(lung) 
HBL-100 
(breast) 
HeLa 
(cervix) 
SW1573 
(lung) 
T-47D 
(breast) 
WiDr 
(colon) 
BJ-hTert 
(fibroblasts) 
2 a 0.29 (0.09) 0.21 (0.04) 0.17 (0.04) 0.20 (0.02) 0.25 (0.04) 0.20 (0.03)  
3 a 0.062 (0.019) 0.088 (0.008) 0.084 (0.022) 0.054 (0.013) 0.210 (0.05) 0.065 (0.010)  
4· 0.036 (0.019) 0.072 (0.008) 0.051 (0.022) 0.030 (0.013) 0.083 (0.05) 0.054 (0.010) 0.23 (0.02) 
5· 0.14 (0.02) 0.32 (0.03) 0.19 (0.01) 0.19 (0.05) 0.33 (0.01) 0.27 (0.03) 0.35 (0.02) 
cisplatin 4.9 (0.2) 1.9 (0.2) 1.8 (0.5) 2.7 (0.4) 17 (3.3) 23 (4.3) 14 (2.4) 
a Taken from refs. [12,13]. b Mean of the least two independent experiments. Standard deviation in parentheses. 
Figure 3. Equivalent enantiomeric molecules in 3 and 4. 
 
Figure 4. Perspective view and atom numbering selection of 4, showing the 
significant weak interactions. 
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crystalline 4 and distillate dry CDCl3, which needs one chloride 
and one proton to occur that can only be provided by the solvent. 
There are references for the abstraction of Cl- and H+ from CHCl3 
and other chlorinated solvents by organometallic complexes,[16] 
nevertheless more experiments are needed before ensuring how 
proceed the transformation of 4 in CDCl3 proceeds. 
 
Conclusions 
The most important conclusions are: the Ru-Zn complex 4 in 
solution transforms slowly and its antiproliferative activity is 
significantly better than those for the complexes formed by its 
decomposition and that for the parent Ru-Co complex 3. 
Therefore, the observed larger antiproliferative activity for 4·is due 
to its composition as bimetallic complex and the adequate 
combination of metals. The biological evaluation of ZnCl2 
revealed that it is not active in any of the studied cell lines. Zinc is 
an essential microelement in the human body and therefore, less 
toxic to humans than non-essential metals like platinum. It plays 
an important physiological role in the protein, nucleic acid as well 
as in the control of gene transcription, in fact is defined as an 
“essential trace element”. Therefore, its properties as antioxidant, 
and its role in cancer prevention require the understanding of the 
complex activity-toxicity relationship.[1a,5a,17] Additionally, whilee 
compound 5 resulted not selective the complex 4 showed to be 3-
8 times less active against a non-tumour cell line. 
Works are in progress to synthesize new bis-metallic Ru-M 
complexes containing biologically active metals and ligands and 
studies targeted to understand the antiproliferative action 
mechanism of these family of bis-heterometal-complexes. 
Experimental Section 
Materials and instruments 
All chemicals were reagent grade and, unless otherwise stated, were used 
and received by commercial suppliers. Likewise, all reactions were carried 
out in a pure argon atmosphere using standard Schlenk-tube techniques 
with freshly distilled and oxygen-free solvents. The complex 
[RuCp(PPh3)2(HdmoPTA-1 P)](CF3SO3)·0.25H2O·(2·0.25H2O) was 
synthesized using the method reported by us.[12] Elemental analysis 
(C,H,N) were performed on a Fisons Instruments EA 1108 elemental 
analyzer. Infrared spectra (KBr, Aldrich) were measured with a Thermo 
Nicolet Avatar 300FT-IR spectrometer. 1H, 31P{1H} and 13C{1H} NMR 
spectra were recorded on a Bruker DRX300 and 500 spectrometers. Peak 
positions are relative to tetramethylsilane and were calibrated against the 
residual solvent resonance (1H) or the deuterated solvent multiplet (13C). 
31P{1H} spectra were recorded on the same instrument operating at 121.49 
and 282.40 MHz, respectively. Chemical shifts for 31P{1H} NMR were 
measured relative to external 85% H3PO4, it was measured with downfield 
values taken as positive. All NMR spectra were obtained at 25 °C. 
Synthesis of [RuCp(PPh3)2-µ-dmoPTA-1kP:2k2N,N’-ZnCl2]·(OTf) 
(4·OTf): a) Potassium tert-butoxide (0.020 g, 0.178 mmol) was added into 
a solution of 2 (0.104 g, 0.090 mmol), which was synthesized as indicated 
in ref 12, in EtOH (10 mL) (Scheme 1). After 15 minutes at r.t. finely 
grounded solid ZnCl2 (0.0133 g, 0.098 mmol) was added. The resulting 
yellow solution was kept for 30 minutes at room temperature and then 
reduced to 5 mL under reduced pressure. The resulting yellow solid was 
recrystallized in EtOH/diethyl ether (1:1), providing yellow microcrystals 
that were filtered and air dried. b) Complex 5 (0.100 g, 0.096 mmol) was 
dissolved into EtOH (5 mL) and then finely grounded solid ZnCl2 (0.0133 
g, 0.098 mmol) was added at room temperature (Scheme 1). After 30 
minutes 5 mL of Et2O was added into the resulting yellow solution and the 
mixture stirred for 5 minutes. The precipitated yellow powder was filtered, 
washed with Et2O (2 x 2 mL) and dried under vacuum. Crystals yield: a) 
0.049 g, 47.4 %; b) 0.069 g, 62.54 %. S25ºC,CHCl3 > 62.5 mg/mL, S25ºC,H2O < 
0.5 mg/mL, S25ºC, EtOH = 10.8 mg/mL. C49H51F3Cl2N3O3P3RuZnS (1149.3 g 
mol-1): Found C: 51.08; H 4.32; N 3.68; calcd. C 51.21; H 4.47; N 3.65%. 
IR (KBr, cm-1): ν(CarH) 3071, 3057; ν(CH) 2961, 2915, 2861; δas(CH) 1434 (m); 
ν(OTf) 1274, 1252, 1170, 1158; ν(C-N) 1029 (m), 1071 (m); δoop(Car-H) 757 
(m), 745 (m); δoop(C=Car) 690 (s). 1H NMR (500.13 MHz, 25ºC, CDCl3): 
δ(ppm) 2.16, 2.15 (bs+bs, NCH3, 6H), 2.97–3.60 (m, PCH2, 6H), 3.63–4.31 
(m, NCH2N, 4H), 4.94 (s, Cp, 5H), 6.93–7.53 (bm, aromatic, 30H). 13C{1H} 
NMR (125.76 MHz, 25 °C, CDCl3): δ(ppm): 44.67 (s, CH3N), 44.72 (s, 
CH3N), 52.39 (d, 1JPC = 25.81 Hz, PCH2NCH3), 57.28 (d, 1JPC = 11.19 Hz, 
PCH2NCH3), 73.85 (s, CH2N), 85.48 (s, Cp), 122.2, (q, 1JCF = 324.55 Hz, 
OSO2CF3), 129.12, 130.95, 133.46, 136.48 (m, PPh3). 31P{1H} NMR 
(202.46 MHz, 25 °C, CDCl3): δ(ppm) -15.10 (t, 2JPP = 39.15 Hz, dmPTA), 
37.50 (d, 2JPP = 39.90 Hz, PPh3).  
Synthesis of [RuCp(PPh3)2(dmoPTA-1kP)]·(OTf) (5·OTf): Potassium 
tert-butoxide (0.0182 g, 0.162 mmol) was added into a tetrahydrofuran (30 
mL) suspension of 2 (0.1777 g, 0.155 mmol) (Scheme 1). The mixture was 
stirred at room temperature for 15 minutes and the solvent removed. The 
yellow residue was treated with CHCl3 (10 mL) and the insoluble solid 
separated out by filtration and washed with CHCl3 (2 x 2 mL). The filtered 
dissolution together with the washing waters were evaporated under 
reduced pressure and the resulting solid washed with THF/diethyl ether 
(1:3), filtered and dried under vacuum. Yield: 0.106 g, 67.51 %. S25ºC,CHCl3 
> 15.5 mg/mL, S25ºC,H2O < 0.5 mg/mL, S25ºC, MeOH > 6.3 mg/mL. 
C49H51F3N3O3P3RuS (1013.00 g mol-1): Found C: 58.18; H 5.18; N 4.10; 
calcd. C 58.10; H 5.07; N 4.15 %. IR (KBr, cm-1): ν(CarH) 3080, 3055; ν(CH) 
2970 ,2931, 2890; δas(CH) 1435 (m); ν(OTf) 1280, 1257, 1222, 1157; ν(C-N) 
1029 (m), 1859 (m); δoop(Car-H) 752 (m), 698 (m); δoop(C=Car) 690 (s). 1H 
NMR (500.13 MHz, 25ºC, CDCl3): δ(ppm) 2.04 (bs, NCH3, 6H), 2.77–3.35 
(m, PCH2, 6H), 3.47–3.53 (m, NCH2N, 4H), 4.78 (s, Cp, 5H), 6.97–7.03, 
7.28–7.35, 7.44–7.48 (bm, aromatic, 12H, 12H, 6H). 13C{1H} NMR (125.76 
MHz, 25 °C, CDCl3): δ(ppm) 43.90, 44.01 (s+s, CH3N), 55.70 (d, 1JPC = 
28.3 Hz, PCH2NCH3), 74.76 (s, CH2N), 85.15 (s, Cp), 128.57-137.14 (m, 
aromatic). 31P{1H} NMR (202.46 MHz, 25 °C, CDCl3): δ(ppm) -7.42 (t, 2JPP 
= 38.24 Hz, dmoPTA), 43.23 (d, 2JPP = 38.24 Hz, PPh3). 
Single Crystal X-ray Crystallography of complex 4·OTf: A single crystal 
with suitable dimensions (0.03 x 0.021 x 0.017) was mounted on a glass 
fibber with cyanoacrylate at room temperature. Data collection was 
performed on a Bruker APEX-II CCD diffractometer in the range 0.952 ≤ 
2θ ≤ 26.372. Data were collected at 100 o K using graphite-
monochromatized Mo-Kα (λ = 0.71073) in the range −13 ≤ h ≤ 9, −26 ≤ k ≤ 
26, −25 ≤ l ≤ 27. The structure was determined by direct methods and 
refined by least-squares procedures on F2 (SHELX-XL) using Olex2 
package.[18,19] The final geometrical calculations, the graphical 
manipulations and the analysis of H-bond network and other 
crystallographic calculations were carried out with Olex2 package.[19] The 
hydrogen atoms were located at the calculated positions. The chloride 
ligand (Cl3) was found to be disordered and refined anisotropically. One 
of the OTf anion of the asymmetric unit is found disordered. Crystal data 
and data collection details are given in Table S1. CCDC 1839217 contains 
the supplementary crystallographic data for this paper. These data can be 
obtained free of charge via the World Wide Web (or from the Cambridge 
Crystallographic Data Centre, 12 Union Road, Cambridge CB21EZ, UK; 
fax: (+44)1223-336-033 or emailing deposit@ccdc.cam.ac.uk). 
Growth inhibition assays: The human solid tumor cell lines A549, HBL-
100, HeLa, SW1573, T-47D and WiDr were used in this study. The human 
fibroblast (non- tumour) cell line BJ-hTert was used to study compound 
selectivity. These cell lines were a kind gift from Prof. G. J. Peters (VU 
Medical Center, Amsterdam, Netherlands). Cells were maintained in 25 
cm2 culture flasks in RPMI 1640 supplemented with 5% heat inactivated 
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fetal calf serum and 2 mM L-glutamine in a 37 °C, 5% CO2, 95% humidified 
air incubator. Exponentially growing cells were trypsinized and re-
suspended in antibiotic containing medium (100 units of penicillin G and 
0.1 mg of streptomycin per mL). Single cell suspensions displaying >97% 
viability by trypan blue dye exclusion were subsequently counted. After 
counting, dilutions were made to give the appropriate cell densities for 
inoculation onto 96-well microtiter plates. Cells were inoculated in a 
volume of 100 μL per well at densities of 2 500 (A549, HBL-100 and HeLa) 
and 5 000 (SW1573, T-47D and WiDr) cells per well, based on their 
doubling times. Compounds were initially dissolved in DMSO at 400 times 
the desired final maximum test concentration. Control cells were exposed 
to an equivalent concentration of DMSO (0.25% v/v, negative control). 
Each agent was tested in triplicate at different dilutions in the range of 1–
100 μM. The drug treatment was started on day 1 after plating. Drug 
incubation times were 48 h, after which time cells were precipitated with 
25 μL ice-cold TCA (50% w/v) and fixed for 60 min at 4 °C. Then the SRB 
assay was performed. The optical density (OD) of each well was measured 
at 530 nm, using BioTek’s PowerWave XS Absorbance Microplate Reader. 
Values were corrected for background OD from wells only containing 
medium. 
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